AstraZeneca puts a lot of money into research and more advanced therapeutic technologies, so that patient outcomes get better and treatment efficiency improves
Metabolic Dysfunction-Associated Steatohepatitis (MASH) MASH, the more aggressive form of nonalcoholic fatty liver disease (NAFLD), is characterized by liver inflammation and damage and can progress to cirrhosis and liver failure
Liu , A.F
Research Scope and Coverage Segment Analysis by Product Type, Nutritional Focus, Consumer Stage, Distribution Channel, Pack Format, End Use, and Region By Product Type: Ready-to-drink Shakes Powder Meal Replacements High-protein Nutrition Drinks Soup and Savory Meal Replacements Bar-based Meal Replacements By Nutritional Focus: High Protein High Fiber Low Sugar Digestive Support Micronutrient-fortified Satiety-support Formulations By Consumer Stage: Active GLP-1 Users Weight-maintenance Users GLP-1 Step-down Users General Weight-management Consumers By Distribution Channel: Pharmacies and Health Stores Supermarkets and Hypermarkets Direct-to-Consumer E-commerce Marketplaces Clinical and Wellness Channels By Pack Format: Single-serve Bottles Sachets Multi-serve Tubs Ready Packs Variety Packs By End Use: Breakfast Replacement Lunch Replacement Structured Weight-management Programs Recovery Nutrition On-the-go Consumption By Region: North America Latin America Europe Asia Pacific Middle East and Africa Research Sources and Bibliography 1
GLP-1 helps reduce intake
The final phase 3 trial can take anywhere from one to four years but varies greatly from drug to drug
